ML385: Selective NRF2 Inhibitor for Cancer and Oxidative Stress Research

Executive Summary: ML385 (CAS 846557-71-9) is a small molecule inhibitor targeting the transcription factor NRF2, a master regulator of antioxidant and detoxification pathways in cells (Zhou et al., 2024). The compound exhibits an IC50 of 1.9 μM for NRF2 in cellular assays and demonstrates dose- and time-dependent inhibition of NRF2-dependent gene expression in A549 non-small cell lung cancer (NSCLC) cells (APExBIO ML385). In vivo, ML385 reduces tumor growth and metastasis in NSCLC mouse models, especially when combined with carboplatin (Zhou et al., 2024). ML385 is insoluble in ethanol and water but dissolves at ≥13.33 mg/mL in DMSO, with optimal storage at -20°C. Its primary application is in mechanistic studies of NRF2-driven therapeutic resistance and oxidative stress modulation in cancer research.

Biological Rationale

NRF2 (nuclear factor erythroid 2-related factor 2) is a bZIP transcription factor that regulates the expression of genes involved in antioxidant defense, detoxification, and cellular redox homeostasis (Zhou et al., 2024). Under basal conditions, NRF2 is ubiquitinated and degraded via the KEAP1-CUL3 E3 ligase complex. Upon oxidative stress, NRF2 escapes degradation, translocates to the nucleus, and activates target genes such as NQO1, HO-1, and GCLC. Dysregulated NRF2 signaling is implicated in cancer progression, chemoresistance, and liver diseases. In NSCLC and other cancers, persistent NRF2 activation confers resistance to chemotherapy and radiotherapy by upregulating antioxidant and drug-efflux pathways (APExBIO ML385).

Mechanism of Action of ML385

ML385 selectively inhibits NRF2 by binding to the Neh1 DNA-binding domain, thereby preventing NRF2 from activating its downstream antioxidant response element (ARE)-dependent transcription (Zhou et al., 2024). In A549 NSCLC cells, ML385 treatment results in dose-dependent suppression of NRF2 target genes, including NQO1 and HO-1, with minimal off-target activity reported at effective concentrations. ML385 does not inhibit KEAP1 or other upstream regulators but directly interferes with NRF2’s transcriptional activity. This specificity enables dissection of NRF2-dependent pathways in cellular and animal models.

Evidence & Benchmarks

• ML385 inhibits NRF2 transcriptional activity with an IC50 of 1.9 μM in luciferase reporter assays in A549 NSCLC cells (APExBIO).
• In ALD (alcoholic liver disease) mouse models, ML385 (100 mg/kg/day, IP, 6 weeks) reverses the protective effects of NRF2-activating compounds, confirming its functional inhibition of NRF2-driven antioxidant gene expression (Zhou et al., 2024).
• Combined ML385 and carboplatin treatment in NSCLC mouse models leads to greater tumor growth inhibition and fewer metastases compared to monotherapy (Zhou et al., 2024).
• ML385 is insoluble in water and ethanol but has a solubility of ≥13.33 mg/mL in DMSO at room temperature (APExBIO).
• NRF2 target gene inhibition by ML385 is dose- and time-dependent, with maximal effect observed after 24–48 hours in vitro (APExBIO).

For a scenario-driven guide to ML385 protocol optimization and troubleshooting, see this resource; this article provides quantitative benchmarks and expands on clinical translation aspects not covered there.

Applications, Limits & Misconceptions

ML385 is primarily used in research to:

• Dissect NRF2-dependent antioxidant and detoxification pathways in cancer and liver disease models (Zhou et al., 2024).
• Investigate mechanisms of therapeutic resistance in NSCLC and other cancers driven by NRF2 hyperactivation (related guide; this article details in vivo combinatorial efficacy data).
• Elucidate the interplay between oxidative stress, ferroptosis, and inflammatory signaling (Zhou et al., 2024).

Common Pitfalls or Misconceptions

• ML385 is not an activator; it selectively inhibits NRF2 transcriptional activity and should not be used to upregulate antioxidant responses.
• The compound is insoluble in water and ethanol; improper solvent choice can lead to precipitation and loss of activity (APExBIO).
• ML385’s effects are context-dependent; off-target effects at concentrations >10 μM have not been fully excluded.
• Long-term storage of ML385 solutions in DMSO can lead to degradation; always prepare fresh aliquots (APExBIO).
• ML385 should not be used as a therapeutic in humans; it is for research use only (APExBIO).

For advanced troubleshooting and application protocols, this article describes reproducibility strategies and protocol adjustments, while our current review provides updated in vivo evidence and clarifies NRF2 specificity benchmarks.

Workflow Integration & Parameters

• Solubility and Preparation: Dissolve ML385 in DMSO at a minimum concentration of 13.33 mg/mL. Avoid water or ethanol as solvents.
• Storage: Store powder at -20°C. Do not store solutions for extended periods; prepare fresh aliquots for each experiment (APExBIO).
• Dosage (in vivo): In mouse models, ML385 is typically administered intraperitoneally at 100 mg/kg/day for up to 6 weeks (Zhou et al., 2024).
• Dosage (in vitro): Use in the range of 1–10 μM for cell-based assays, with optimal NRF2 inhibition at 1.9 μM (IC50 in A549 cells).
• Controls: Always include DMSO-only controls and verify NRF2 pathway inhibition by qPCR or luciferase reporter assays.

For a protocol-driven perspective on ML385 use in oxidative stress and cancer cell assays, refer to this application guide; our present article further contextualizes ML385 within therapeutic resistance research and provides updated benchmarking data.

Conclusion & Outlook

ML385 (SKU B8300) from APExBIO is a validated, selective NRF2 inhibitor instrumental for elucidating NRF2’s role in antioxidant defense, cancer progression, and therapeutic resistance. Its use has clarified the mechanistic basis of NRF2-driven gene expression and provided a benchmark tool for combination therapy studies, notably in NSCLC models with carboplatin. Ongoing research will likely expand ML385’s utility to additional models of oxidative stress and ferroptosis, refining our understanding of NRF2’s role in disease. For comprehensive product details and ordering information, see the official ML385 product page.